Web  accessibility  for the disabled Home Contact Us Email Us Shopping Cart Follow us on Facebook Follow us on Twitter ForLifeWithoutLimits Channel
AAFA
AAFA Education Advocacy Research
  
AAFA Home Page
ASTHMA ALLERGIES AAFA
 
 
AAFA
AAFA
AAFA
AAFA
You Can Help!
Take Action
Certification Program
Educational Resources
Ask the Allergist
Find a Chapter
Find a Support Group
Find a Clinic
Health Professionals
En Español
Newsroom
Contact AAFA
Login


1-800-7-ASTHMA
info@aafa.org
AAFA
AAFA Responds to Threatened Warning on Eczema Treatments

On March 10, 2005 the FDA announced their intention to include a black box warning and to develop a patient medication guide for the topical calcineurin inhibitors, Elidel and Protopic, to treat eczema.  Both measures are typically considered extreme and are usually reserved for urgent situations requiring an immediate public health warning. In this case, though, the dermatology and allergy communities do not agree with FDA’s intended actions. 

 

On April 5, AAFA sent a letter to the FDA echoing the concerns of the allergy and dermatology communities that a black box warning and medication guide do not seem to be the best mechanisms for communicating risk in this situation.  AAFA argues in the letter that the millions of prescriptions for these drugs over the past few years reflects the unmet need for alternative treatments and, potentially, the growing number of Americans who suffer from allergic disease.

 

The letter asks the agency to reconsider and to renew efforts with its advisors and with the drug sponsors to find alternative outreach mechanisms to properly educate health care professionals and patients on these important therapies. If you have any questions or need further information, please contact Mo Mayrides, AAFA Director of Public Policy, at (202) 466-7643 x273 or by email at mo@aafa.org.

Download a copy of the letter to the FDA.

 
Privacy Policy Home Contact Us Asthma Allergies Food Allergies Donate

 

Ask the allergist Shop Our Catalog Donate to AAFA